Press releases & announcements
17 January, 2019
RhoVac reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study
17 December, 2018
RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study
14 November, 2018
RhoVac participates in international business conferences in the UK and the United States
Press Releases and Company Announcements published before 1 May 2017 in Swedish only.
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.